Evidence map›Paper›PMID 41502642›Full record

ArticleACS omega2025

Dual-Site Chemically Engineered MNAzymes for One-Pot Isothermal Detection of MicroRNAs.

Yuying Huang, Can Jia, Yajuan Tang, Jun Zhang, Ruolian Zhao, Jihong Zhang, Lin Chai

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuying HuangDepartment of Clinical Laboratory, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming 650599, China.ORCID https://orcid.org/0009-0005-5290-5498
Can JiaDepartment of Clinical Laboratory, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming 650599, China.ORCID https://orcid.org/0009-0000-2552-6322
Yajuan TangDepartment of Clinical Laboratory, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming 650599, China.ORCID https://orcid.org/0009-0006-7196-3877
Jun ZhangDepartment of Clinical Laboratory, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming 650599, China.ORCID https://orcid.org/0009-0008-9283-3021
Ruolian ZhaoDepartment of Clinical Laboratory, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming 650599, China.ORCID https://orcid.org/0009-0000-9537-2285
Jihong ZhangMedical School of Kunming University of Science and Technology, Kunming 650500, China.
Lin ChaiDepartment of Clinical Laboratory, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming 650599, China.ORCID https://orcid.org/0009-0000-6084-3585

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sensitive detection of microRNAs (miRNAs) remains challenging due to their low abundance and sequence similarity. Conventional DNAzyme- and multicomponent nucleic acid enzyme (MNAzyme)-based assays are enzyme-free but often limited by poor catalytic turnover. Here, we present a dual-site chemically engineered MNAzyme platform that integrates xeno-nucleic acid modification within the catalytic core and locked nucleic acid substitution within the target-binding arms to synergistically enhance catalytic and recognition efficiency. The resulting hybrid, termed LXMz, exhibits an ∼760-fold improvement in catalytic rate and an ∼450-fold increase in sensitivity relative to the unmodified MNAzyme. Under isothermal, one-pot conditions, LXMz achieves the quantitative detection of miR-92a with a limit of detection of 2 pM while maintaining single-base specificity. By combining catalytic enhancement and hybridization stabilization within a unified molecular design, this study establishes a new chemical engineering principle for constructing robust, enzyme-free biosensors. The LXMz framework provides a versatile and sensitive platform for miRNA analysis and holds promise for liquid biopsy and point-of-care diagnostics.

Identifiers

PMID41502642
PMCPMC12771414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.